Ambry Genetics Corporation; Tempus AI, Inc. CA · Latest: 2024-12-20 CA Notice complete
Agency description Tempus AI, Inc. will acquire Ambry Genetics Corporation. Both parties previously partnered to distribute germline sequencing for inherited cancer risk and this acquisition intends to further expand inherited risk screening for cancer patients.
CA Office of Health Care Affordability (HCAI), “Transaction Type” column, hcai.ca.gov State reviews State Agency Status Stage Source CA Office of Health Care Affordability (HCAI) CMIR Waived WAIVED NOTICE Agency record
Trail Dates as published by the agency unless marked.
2024-12-20 CA Notice complete
Date Submission Completed: December 20, 2024
Not dated CA Cost and market impact review waived
CMIR Waived
No changes observed since the initial load (CA 2026-09-28 ).
Parties as filed Documents (2) Evidence One agency record. It is not grouped with any other.
Names as filed and source keys State Title as printed Source key Key method CA Ambry Genetics Corporation / and / Tempus AI, Inc. material-change-transaction-notice-ambry FIRST_DOCUMENT_SLUG
Observed by DocketTrail State Source key First seen by DocketTrail (UTC) Last checked (UTC) Page checked CA material-change-transaction-notice-ambry 2026-09-26 07:15 2026-11-21 11:15 hcai.ca.gov
Captures